New York, United States
Formation Bio, founded in 2013, is revolutionizing the pharmaceutical sector by leveraging AI-driven innovations for more efficient drug development. With the slogan "Bringing new treatments to patients faster and more efficiently," the company provides proprietary technology platforms that enhance trial design, expedite completion, and improve data quality.
The company specializes in acquiring clinical-stage drugs from established pharmaceutical and biotech entities, with the intent to streamline development and maximize asset value. This approach not only accelerates drug availability to patients but also aligns with the company’s mission of advancing health care solutions.
Formation Bio has garnered significant industry recognition, earning accolades such as the 2025 CNBC Disruptor 50, 2025 Fierce 15 Award, and the 2024 Endpoints 11 Award. These honors underscore its impact and potential in the competitive biotech landscape. Despite its strategic advantages, details on recent fundraising or current headquarters remain unspecified. For stakeholders in search of innovative, high-impact ventures, Formation Bio represents a compelling opportunity.
